Nektar Therapeutics (NKTR) Tops Q3 EPS by 1c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $66.84 -0.39%
EPS Growth %: -215.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: -215.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $24.1 million versus the consensus estimate of $21.26 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- DA Davidson Reiterates Buy Rating on Vulcan Materials Company (VMC)
- Morgan Stanley Upgrades Coal India Ltd (COAL:IN) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
